CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
NIC5-15 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00470418
NCT00470418Phase 2Completed
CompareCT.gov

Development of NIC5-15 in the Treatment of Alzheimer's Disease

VA Office of Research and Development·interventional·Posted May 7, 2007·Updated Jan 9, 2017

In Brief

A Phase 2 clinical trial evaluating NIC5-15 and Placebo for Alzheimer Disease and Dementia. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of NIC5-15in the treatment of Alzheimer's Disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease, Dementia
CountriesUnited States
CollaboratorsNational Center for Complementary and Integrative Health (NCCIH), Humanetics Corporation

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 7, 2007
Enrollment StartJan 1, 2007
Primary CompletionAug 1, 2008
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 19.2 years ago

Interventions

NIC5-15drug

a natural product, found in many foods and plants with mild insulin sensitizing effects

Placebodrug

placebo comparator